Recombinant Human B7-2/CD86 Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Mature human B7-2 consists of a 224 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 61 aa cytoplasmic tail (3, 4). Within the ECD, human B7-2 shares 59% aa sequence identity with mouse and rat B7-2. Alternative splicing of human B7-2 generates additional isoforms that lack both Ig-like domains or a region that includes the transmembrane segment. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (4-7), as well as on vascular endothelial cells (8). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3-5, 7, 9-11). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up‑regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3-5, 7, 9, 10). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (12). B7-2 is expressed earlier than B7-1 following APC activation (6), and both proteins bind with higher affinity to CTLA-4 than to CD28 (10). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (13). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (14). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (15).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 4 applications: Bioassay, Cell Culture, ELISA (Standard), Flow Cytometry.

Showing Publications 1 - 5 of 5.

Publications using 141-B2	Applications	Species
Popugailo, A;Rotfogel, Z;Levy, M;Turgeman, O;Hillman, D;Levy, R;Arad, G;Shpilka, T;Kaempfer, R; The homodimer interfaces of costimulatory receptors B7 and CD28 control their engagement and pro-inflammatory signaling Journal of biomedical science 2023-06-28 [PMID: 37381064] (Cell Culture, Human)	Cell Culture	Human
H Sic, M Speletas, V Cornacchio, M Seidl, M Beibel, B Linghu, F Yang, E Sevdali, AE Germenis, EJ Oakeley, E Vangreveli, AW Sailer, E Traggiai, H Gram, H Eibel An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome Front Immunol, 2017-12-15;8(0):1824. 2017-12-15 [PMID: 29375547] (Flow Cytometry, Human)	Flow Cytometry	Human
Lutz Jermutus A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding J. Immunol., 2016-11-23;0(0):. 2016-11-23 [PMID: 27881707] (Bioassay)	Bioassay
Choi J, Goh G, Walradt T, Hong B, Bunick C, Chen K, Bjornson R, Maman Y, Wang T, Tordoff J, Carlson K, Overton J, Liu K, Lewis J, Devine L, Barbarotta L, Foss F, Subtil A, Vonderheid E, Edelson R, Schatz D, Boggon T, Girardi M, Lifton R Genomic landscape of cutaneous T cell lymphoma. Nat Genet, 2015-07-20;47(9):1011-9. 2015-07-20 [PMID: 26192916] (Flow Cytometry, Human)	Flow Cytometry	Human
Sakthivel P, Shively V, Kakoulidou M The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm. J. Intern. Med., 2007-04-01;261(4):399-407. 2007-04-01 [PMID: 17391115] (ELISA (Standard))	ELISA (Standard)

Array 141-B2

• B7-2/CD86 Antibodies
• B7-2/CD86 Antibody Pairs
• B7-2/CD86 ELISA Kits
• B7-2/CD86 Proteins
• B7-2/CD86 Proteins and Enzymes
• B7-2/CD86 ELISA